Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) …

tucatinib
estrogen receptor
breast cancer
trastuzumab
MRI
  • 24 views
  • 18 Dec, 2020
  • 111 locations
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus the treatment with paclitaxel in combination with HER2 blockade.

hormone therapy
primary tumor
invasive breast cancer
paclitaxel
trastuzumab
  • 17 views
  • 25 Dec, 2020
  • 63 locations
Tucatinib Trastuzumab and Capecitabine for the Treatment of HER2+ LMD

positive breast cancer.

hormone therapy
invasive breast cancer
trastuzumab
international normalized ratio
leptomeningeal disease
  • 0 views
  • 20 Jul, 2020
  • 1 location
Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab

This is a study to evaluate the toxicity profile of neratinib in combination with trastuzumab in patients with early stage breast cancer with the use of anti-diarrheal prophylaxis. The anti-diarrheal medications being tested in this trial are loperamide and crofelemer. Crofelemer is an anti-diarrheal, enteric-coated drug product for oral administration. …

hormone therapy
trastuzumab
endocrine therapy
ejection fraction
breast cancer staging
  • 62 views
  • 26 Dec, 2020
  • 2 locations
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint inhibitor atezolizumab or not.

trastuzumab
epidermal growth factor
cyclophosphamide
growth factor
pd-l1
  • 2 views
  • 25 Dec, 2020
  • 11 locations
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the leptomeninges.

  • 0 views
  • 26 Nov, 2020
  • 1 location
DS-8201a for trEatment of aBc BRain Mets And Her2[+] Disease

This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial

primary tumor
invasive breast cancer
paclitaxel
trastuzumab
MRI
  • 0 views
  • 03 Dec, 2020
  • 17 locations
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.

  • 0 views
  • 27 Dec, 2020
  • 6 locations
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory) and has spread to other places in the body (metastatic). Anti-cancer …

hormone therapy
trastuzumab
bisphosphonate
endocrine therapy
ejection fraction
  • 2 views
  • 09 Dec, 2020
  • 1 location
T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

This phase II trial studies how well abemaciclib with or without T-DM1 works for the treatment of HER2-positive breast cancer that has spread to other places in the body (metastatic). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. T-DM1 is …

  • 0 views
  • 27 Dec, 2020
  • 8 locations